We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Names New Director for the Office of Generic Drugs

FDA Names New Director for the Office of Generic Drugs

February 19, 2019

CDER Director Janet Woodcock announced that Sally Chloe will be the new director of the Office of Generic Drugs at the end of the month.

Chloe, who served as CDER’s Office of Study Integrity and Surveillance’s deputy director for the past two years, will collaborate with outgoing OGD director Kathleen Uhl to ensure a smooth transition.

Chloe worked with the agency’s review divisions and served for five years on the Office of Clinical Pharmacology’s metabolism and endocrinology team, guiding scientists in clinical and pharmacology reviews and NDA, BLA and IND evaluations. Prior to joining the agency, she was a research manager at Bristol-Myers Squibb and a clinical pharmacology manager at Pfizer.

View today's stories

Pharmaceuticals Regulatory Affairs

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 21Jun

    Medical Device Reporting: Best Practices and Common Pitfalls

  • 22Jun

    Meet CDRH’s New Strategic Priorities: Where the Center is Headed and How Devicemakers Can Keep Up

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Accelus FlareHawk Interbody Fusion System Cleared

  • Use of Pfizer’s Paxlovid Spikes by 315 Percent

  • Linear Health Sciences Gets FDA Clearance for Its Orchid Safety Release Valve

  • Roche’s Faricimab Gains UK Approval Via International Program

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing